This process ultimately results in enhanced anti-tumor immune activity, especially when combined with immune checkpoint inhibitors (77).In addition, therapies that target lipid metabolism, such as the inhibition of FASN, have been shown to increase immune checkpoint inhibitor efficacy in melanoma by altering the TME and promoting tumor immunogenicity (38, 79). The gene discussed is FASN; the disease is melanoma.